newsfilter
← Earnings
Earnings Releases·

Ultragenyx Pharmaceutical Inc. — Third Quarter 2026 Earnings Summary

  • Revenue reached $173 million for Q3 2026, up from $160 million in the prior year period, while net loss narrowed to $118 million ($1.16 per share) from $180 million ($1.81 per share) in the same 2025 quarter.
  • The company reaffirmed full-year 2026 revenue guidance of $730 million to $760 million and expects to achieve GAAP profitability in 2027, supported by projected R&D and SG&A expense reductions.
  • Two major product approvals were secured in the quarter (GENGLYCOS and FAYUVI), alongside the execution of definitive agreements to sell associated Priority Review Vouchers for a combined $413 million, with net proceeds expected at approximately $350 million.
  • Strategic restructuring includes a 20% headcount reduction to a workforce of ~1,000 employees, the termination of the UX701 program, and the winding down of the GTX-102 program to focus on commercial execution.
Company
ULTRAGENYX PHARMACEUTICAL INC
Sector
Healthcare
Industry
Biotechnology